It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Deep understanding of the genomic and immunological differences between Chinese and Western lung cancer patients is of great importance for target therapy selection and development for Chinese patients. Here we report an extensive molecular and immune profiling study of 245 Chinese patients with non-small cell lung cancer. Tumor-infiltrating lymphocyte estimated using immune cell signatures is found to be significantly higher in adenocarcinoma (ADC, 72.5%) compared with squamous cell carcinoma (SQCC, 54.4%). The correlation of genomic alterations with immune signatures reveals that low immune infiltration was associated with EGFR mutations in ADC samples, PI3K and/or WNT pathway activation in SQCC. While KRAS mutations are found to be significantly associated with T cell infiltration in ADC samples. The SQCC patients with high antigen presentation machinery and cytotoxic T cell signature scores are found to have a prolonged overall survival time.
The relationship between genomic alteration and immune context in non-small cell lung cancer (NSCLC) is complex. Here, the authors analyse the molecular and immunological landscape of 245 Chinese patients with NSCLC and find low immune infiltration correlates with genomic alterations.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangdong Lung Cancer Institute, Guangzhou, China (GRID:grid.410643.4)
2 Peking University People’s Hospital, Beijing, China (GRID:grid.411634.5) (ISNI:0000 0004 0632 4559)
3 1st Hospital of Jilin University, Thoracic Surgery, Changchun, China (GRID:grid.64924.3d) (ISNI:0000 0004 1760 5735)
4 Zhongshan Hospital, Fudan University, Shanghai, China (GRID:grid.413087.9) (ISNI:0000 0004 1755 3939)
5 Janssen R&D China, Shanghai, China (GRID:grid.413087.9)
6 Janssen R&D, Spring House, USA (GRID:grid.413087.9)
7 Novocraft Technologies, Petaling Jaya, Malaysia (GRID:grid.413087.9)
8 Jilin Provincial Cancer Hospital, Department of Medical Oncology, Changchun, China (GRID:grid.413087.9)
9 Cancer Institute of Jiangsu Province, Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing, China (GRID:grid.413087.9)